Hong Kong Stock Movement
BAO PHARMA-B fell 10.06%. Based on recent key news:
<ol>
<li>
On December 30, BAO PHARMA-B announced plans to implement an H-share full circulation plan and submitted filing materials to the China Securities Regulatory Commission, planning to convert 63.1163 million unlisted shares into H-shares, accounting for 19.36% of the company's total issued shares. This move may lead to short-term fluctuations in the company's stock price.
</li>
<li>
On December 31, Zhitong Finance reported that since its listing on December 10, BAO PHARMA-B's stock price has surged over 200% in 14 trading days. The recent announcement of the full circulation plan may trigger a market reassessment of the company's future liquidity and valuation, leading to stock price volatility.
</li>
<li>
On December 30, Caihua News pointed out that BAO PHARMA-B's full circulation plan still requires approval from the China Securities Regulatory Commission and the Hong Kong Stock Exchange, and the uncertainty regarding the approval process may have exacerbated stock price fluctuations. The increase in liquidity in the Hong Kong stock market attracts institutional investors.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Innovent Biologics rose 2.62%. Based on recent news,
<ol>
<li>
On December 30, an alliance initiated by Hainan Lecheng Hongyuan Medical Technology Innovation Development Research Institute and other institutions aims to build a full-chain platform support system, focusing on key areas such as innovative devices and innovative drugs. This move helps promote Innovent Biologics' development in the innovative drug sector, enhances market confidence, and drives stock price increases.
</li>
<li>
On December 29, the 2025 Third Anhui Province Medical and Health Information Technology Innovation Conference was successfully held in Hefei, emphasizing the need to seize opportunities for digital transformation and promote the implementation of intelligent medical products. As a participant in the medical innovation field, Innovent Biologics benefits from the overall positive trend in the industry, leading to an increase in stock price. The trend of innovation and digital transformation in the medical industry is evident.
</li>
</ol>
BeiGene rose 2.45%. Based on recent news,
<ol>
<li>
On January 2, Cell Death Dis reported that inhibiting the TIGIT protein is expected to assist the immune system in targeting cancer cells. This research progress has enhanced market confidence in BeiGene's innovative drug development, driving stock price increases.
</li>
<li>
On January 1, Caixin reported that Xiaomi's YU7 delivered over 150,000 units in six months, 2.3 times that of SU7 during the same period. Although there is no direct correlation with BeiGene, it demonstrates strong market interest in technology and innovation, indirectly boosting investment sentiment in related sectors.
</li>
<li>
On December 31, private equity researcher Liu Yan stated that the overall performance of pharmaceutical investments in 2025 will be &#34;ice and fire intertwined,&#34; but the CXO sector related to innovative drugs will perform prominently. As an innovative drug company, BeiGene benefits from this trend, leading to an increase in stock price. There is a clear differentiation in the pharmaceutical sector, with innovative drugs benefiting.
</li>
</ol>
CanSino Biologics fell 1.06%. Based on recent key news:
<ol>
<li>
On December 31, CanSino Biologics' innovative drug Erythropoietin made significant progress in the international market, gaining attention from multiple overseas media outlets. The news that Erythropoietin outperformed Pembrolizumab has been referred to as the &#34;DeepSeek moment&#34; in the biotechnology industry, enhancing CanSino Biologics' international influence, but it has not yet been reflected in the stock price
</li>
<li>
On December 30th, the integrated research, production, and sales services in Huangpu District provided convenience for Kangfang Biotech, accelerating the closed-loop conversion from samples to products. However, despite being beneficial for long-term development, the short-term impact on stock prices is limited.
</li>
<li>
On December 31st, Kangfang Biotech marked China's coordinates on the global R&amp;D map, with all drugs advancing to clinical phase II approved for market launch, demonstrating a high success rate in R&amp;D. Nevertheless, concerns about short-term profitability may lead to a decline in stock prices. The globalization trend in the biopharmaceutical industry is evident.
</li>
</ol>
Stocks Ranked Among the Top in Industry Market Value
Kanglongda Biotech-B rose by 0.71%. Based on recent key news:
<ol>
<li>
On January 1st, three innovative drugs from Kanglongda Biotech-B were successfully included in the &#34;National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and Commercial Health Insurance Innovative Drug Catalog (2025),&#34; reducing treatment costs, alleviating patients' financial pressure, and driving up stock prices. Source: Zhitong Finance
</li>
<li>
On December 29th, the global CAR-T therapy market was active, with frequent mergers and acquisitions and licensing transactions among related companies. Although Kanglongda did not participate directly, the overall industry outlook improved, boosting market confidence. Source: Zhitong Finance
</li>
<li>
On January 1st, the inclusion of Kanglongda Biotech-B's drug catalog in medical insurance further solidified its market position and enhanced investor confidence. Source: Zhitong Finance. The favorable policies for the innovative drug industry have led to significant capital inflows
</li>
</ol>

02659

BAO PHARMA-B fell 10.06%; Innovent Biologics rose 2.62%, with a transaction volume of HKD 120 million; BeiGene rose 2.45%, with a transaction volume of HKD 63.77 million; CanSino Biologics fell 1.06%, with a transaction volume of HKD 50.03 million; Kelun-Biotech rose 0.71%, with a market capitalization of HKD 92.1 billion

HK Stock Movers Tracker

BAO PHARMA-B

Hong Kong Stock Movement: BAO PHARMA-B's full circulation plan triggers a sharp decline in stock price, as the market reassesses liquidity and valuation risks